Otsuka Collaborates with Chip Ganassi Racing and Driver Kyle Larson at Charlotte

US Pharma Company Otsuka to Race on the No. 42 Chevy at Charlotte in the Monster Energy NASCAR Cup Series and XFINITY Series to Raise Awareness for Mental Health CONCORD, N.C. (Oct. 4, 2017) – Chip Ganassi Racing (CGR) and Otsuka America Pharmaceutical, Inc. (Otsuka) announced today a collaboration that will include the pharmaceutical company’s logo on both the No. 42 Chevrolet SS in the Monster Energy NASCAR Cup Series (MENCS) and the No. 42 Chevrolet Camaro in the NASCAR XFINITY Series (NXS).   Driver Kyle Larson will meet with members of Otsuka’s leadership team and the advocacy group Mental Health America on Saturday October 7th for a roundtable discussion on stress, mental illness, and the importance of monitoring mental health. Parts of that discussion will be shared on social media. NOTES OF INTEREST:
  • Racing Toward Mental Health Awareness: The collaboration between Otsuka and Chip Ganassi Racing seeks to raise awareness of mental illness in America, to reduce the stigma associated with mental health, and to encourage screening for mental health conditions. The race in Charlotte comes at the end of Mental Illness Awareness Week, a nationally recognized awareness week of national activities focused on encouraging mental wellness in America. 
  • Crossing Borders: This new collaboration with Otsuka pairs Kyle Larson, who is half-Japanese, with a US pharmaceutical company with Japanese roots. Larson and CGR currently have a partnership with JX Nippon, the largest oil company in Japan. Larson is the only Asian-American currently racing in one of NASCAR’s national touring series. 
  • Playoff Push: Larson handily made it through Round 1 of the NASCAR Playoffs, picking up three top-five finishes and earning one bonus point with a stage win at Dover. This week Larson heads to Charlotte, the first race of the second round, sitting third in the playoff standings, 25 points behind the leader. 
  • (Forty)Two for One: This weekend at Charlotte, Otsuka will get two shots at a trip to the victory lane with the same number as it champions the race towards mental health awareness. On Saturday, Alex Bowman will pilot the No. 42 Chevrolet Camaro in the NXS race. It will be the first start of the season for Bowman in CGR’s No. 42 NXS car. The following day, Otsuka will again be on No. 42, but this time with Kyle Larson behind the wheel of the No. 42 Chevrolet SS. 
  • Congressman Richard Hudson (NC – 8th District) will join Otsuka and Kyle Larson on the track on October 8th to help promote mental wellness.
CGR QUOTEBOARD:
  • Steve Lauletta, President, Chip Ganassi Racing: “We are very excited to be welcoming Otsuka to not only our team, but also to the sport of NASCAR, especially given their work around mental health. Kyle’s unique background allows our team the opportunity to reach out to unique partners, and we’re looking forward to bringing on another company with Japanese roots to work with Kyle and the No. 42 team.” 
  • Kabir Nath, President and CEO, North America Pharmaceutical Business, Otsuka America Inc.: “It is an honor to collaborate with Chip Ganassi Racing, Kyle Larson, and Mental Health America to champion mental wellness. We are excited for the opportunity to reach NASCAR fans and have them join us in our efforts to help drive awareness while reducing the stigma of mental illness.  
  • Kyle Larson, Driver No. 42 Chevrolet SS: “I’m excited to have Otsuka join our team. Mental wellness is important for all Americans, and through this relationship I hope we can help raise awareness of the impact mental illness has on all Americans, to reduce stigma, and encourage screening for mental health conditions.” 
  • Congressman Richard Hudson (NC-8th District) - “We are proud to join Otsuka, Mental Health America and Chip Ganassi Racing to raise much-needed awareness around mental wellness and health issues facing our nation. Now more than ever, people need to receive proper screening and treatment.” 
  • Paul Gionfriddo, President and CEO, Mental Health America “For more than a century, Mental Health America has been working for prevention, early intervention, sound treatment, and recovery.  We are hoping to help people recognize early symptoms such as loss of sleep, exhaustion for no reason, feeling low, anxious, or hearing voices, that should lead us to take action. Our #B4Stage4 effort focuses on early intervention and we’re hoping our online screenings can be a great first step. http://www.mentalhealthamerica.net/mental-health-screening-tools.”
About Otsuka: Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These companies’ 1,800 employees in the U.S. develop and commercialize medicines in mental health, oncology, cardio-renal and nephrology, using cutting-edge technology to address unmet healthcare needs.  Otsuka’s most recently approved product in the U.S. is indicated for the treatment of adults with schizophrenia and as an adjunctive therapy to antidepressant medications for adults with major depressive disorder.  In the medical device field, Otsuka markets a urea breath test used to detect H. pylori infection in the digestive tract. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately USD 11 billion in 2016. All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/. About Mental Health America: Mental Health America (www.mentalhealthamerica.net), founded in 1909, is the nation’s leading community-based network dedicated to helping all Americans achieve wellness by living mentally healthier lives. With our 228 affiliates across the country, we touch the lives of millions—Advocating for changes in mental health and wellness policy; Educating the public & providing critical information; and Delivering urgently needed mental health and wellness Programs and Services. About Chip Ganassi Racing: Chip Ganassi has been a fixture in the auto racing industry for over 30 years and is considered one of the most successful as well as innovative owners the sport has anywhere in the world. Today his teams include four cars in the Verizon IndyCar Series, two cars in the Monster Energy NASCAR Cup Series, two cars in the NASCAR XFINITY Series, two factory Ford GT’s in the IMSA WeatherTech SportsCar Championship, and two factory Ford GT’s in the FIA World Endurance Championship. Overall his teams have 18 championships and more than 190 victories, including four Indianapolis 500s, a Daytona 500, a Brickyard 400, seven Rolex 24 At Daytonas, the 12 Hours of Sebring and the 24 Hours of Le Mans. Ganassi boasts state-of-the-art race shop facilities in Indianapolis and Concord, N.C., with a corporate office in Pittsburgh, Pa. For more information log onto www.chipganassiracing.com